Ad.26.COV2.S新冠疫苗接种后血小板减少症:向疫苗不良事件报告系统的报告
研究分析了2021年2月至12月美国疫苗不良事件报告系统(VAERS)中接种Ad.26.COV2.S新冠疫苗后血小板减少症的报告,共识别100例,多数为严重病例(84%),包括6例死亡,粗略报告率为每10万剂0.61例,观察与预期比值比为2.43(95%CI 1.97, 2.95),提示接种后血小板减少症风险增加。
要点
- 接种Ad.26.COV2.S后报告100例血小板减少症,84%为严重病例,含6例死亡。
- 中位血小板计数为33,000/µL,15%的病例血小板计数≤5,000/µL。
- 观察与预期比值比为2.43(95%CI 1.97, 2.95),提示风险增加。
核心结论
- 这些发现提示接种Ad.26.COV2.S后血小板减少症风险增加。
研究设计与样本
- 对2021年2月至12月疫苗不良事件报告系统(VAERS)被动监测数据的分析,共纳入100例血小板减少症报告。
- 分析了人口学、临床特征、实验室值和相关病史,并基于疫苗接种数据和一般未接种人群背景率计算观察与预期比值比。
主要发现
- 截至2021年12月31日,VAERS中识别100例接种Ad.26.COV2.S后血小板减少症报告。
- 中位血小板计数为33,000/µL(四分位距8,000-86,000),15例(15%)报告血小板计数≤5,000/µL。
- 血小板减少症中位发病时间为9天(四分位距3-18.5),大多数病例(69例,69%)在接种后14天内开始。
- 大多数病例(84例,84%)为严重病例,包括6例死亡。
- 美国成人约接种16,292,911剂Ad.26.COV2.S,粗略报告率为每10万剂0.61例血小板减少症;总体估计观察与预期比值比为2.43(95%CI 1.97, 2.95)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization for Ad.26.COV2.S COVID-19 vaccine. As part of post-authorization safety surveillance, the FDA has identified a potential safety concern for thrombocytopenia following receipt of Ad.26.COV2.S COVID-19 vaccine. METHODS: Reports of thrombocytopenia were identified in a passive reporting system (Vaccine Adverse Event Reporting System; VAERS) February-December 2021. Demographics, clinical characteristics, laboratory values, and relevant medical history were reviewed. The reporting rate was analyzed, including calculation of the observed-to-expected ratio based on vaccine administration data and the background rate of thrombocytopenia in the general (unvaccinated) population. RESULTS: As of December 31, 2021, 100 reports of thrombocytopenia were identified in VAERS following vaccination with Ad.26.COV2.S. The median platelet count was 33,000 per µL (interquartile range 8,000-86,000). Fifteen reports (15%) documented a platelet count of 5,000 per µL or lower. The median time to onset of thrombocytopenia was 9 days (interquartile range 3-18.5), with most cases (69; 69%) beginning within 14 days after vaccination. A large majority of cases (84; 84%) were serious, including six deaths. With approximately 16,292,911 doses of Ad.26.COV2.S administered to adults in the US, the crude reporting rate was 0.61 cases of thrombocytopenia per 100,000 doses administered. The overall estimated observed-to-expected rate ratio was 2.43 (95% CI 1.97, 2.95). CONCLUSIONS: These findings suggest an increased risk of thrombocytopenia following receipt of Ad.26.COV2.S.
引用
- Woo EJ, Dimova RB. Thrombocytopenia after Ad.26.COV2.S COVID-19 vaccine: Reports to the vaccine adverse event reporting system. Vaccine. 2022. PMID: 35667915. doi:10.1016/j.vaccine.2022.05.078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。